Research programme - cancer therapeutics - Artios Pharma

Drug Profile

Research programme - cancer therapeutics - Artios Pharma

Alternative Names: DDR - cancer therapeutics - Artios Pharma; Pol-theta

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology
  • Developer Artios Pharma; Masaryk University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA repair enzyme modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 05 Mar 2018 Artios in-licenses first nuclease drug development programme from Masaryk University
  • 23 Jun 2017 Early research in Cancer in Czech Republic (Parenteral)
  • 12 Jun 2017 Artios Pharma and Masaryk University agree to develop cancer therapeutics in Czech Republic for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top